Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Minority Interest: 2020-2022

Historic Minority Interest for BIO-TECHNE (TECH) over the last 1 years, with Jun 2022 value amounting to -$759,000.

  • BIO-TECHNE's Minority Interest fell 109.19% to -$759,000 in Q2 2022 from the same period last year, while for Jun 2022 it was -$759,000, marking a year-over-year decrease of 109.19%. This contributed to the annual value of -$759,000 for FY2022, which is 109.19% down from last year.
  • According to the latest figures from Q2 2022, BIO-TECHNE's Minority Interest is -$759,000, which was up 27.99% from -$1.1 million recorded in Q1 2022.
  • BIO-TECHNE's 5-year Minority Interest high stood at $8.9 million for Q4 2020, and its period low was -$1.1 million during Q1 2022.
  • Its 3-year average for Minority Interest is $4.4 million, with a median of $7.6 million in 2021.
  • Data for BIO-TECHNE's Minority Interest shows a maximum YoY tumbled of 112.42% (in 2022) over the last 5 years.
  • Over the past 3 years, BIO-TECHNE's Minority Interest (Quarterly) stood at $8.9 million in 2020, then slumped by 105.12% to -$458,000 in 2021, then crashed by 109.19% to -$759,000 in 2022.
  • Its Minority Interest stands at -$759,000 for Q2 2022, versus -$1.1 million for Q1 2022 and -$458,000 for Q4 2021.